Healthcare Room III
The Remedy Room
The legislative architecture to dismantle the Wrongful Denial Echo Chamber. The documented case that proves the mechanism exists. And the independent voices that are making it impossible to look away.
Contents
- The Legislative Architecture
- S.3829 — Corporate Crimes Against Healthcare Act
- S.3822 — Break Up Big Medicine Act
- H.R. 6852 — Advanced Wound Care and Regenerative Medicine Access and Reform Act
- The Clinical Integrity & Patient Safety Amendment
- Denial on Trial — A Framework for Medical Due Process
- The PSI Briefing — Documented Evidence of Prior Knowledge Omission
- Independent Voices
The Legislative Architecture
The Wrongful Denial Echo Chamber is not a single problem — it is an interlocking system of failures. Dismantling it requires interlocking solutions. Below is the complete framework, with each piece of legislation named, its function explained, and its relationship to the others.
S.3829 is the sword.
Criminal and civil penalties for executives whose decisions cause patient harm. Unjust enrichment clawbacks. The force of law aimed at the corporation.
The Clinical Integrity Amendment is the shield.
Mandatory State Medical Board referral when an IRE overturn proves Prior Knowledge Omission. The personal accountability that S.3829 doesn't reach — stripping the license from the physician who pulled the trigger.
The Buffer Fund is the refuge.
Capitalized by S.3829's 500% clawback penalties, it provisionally covers denied care during appeal — so patients are not forced to survive the delay while their condition deteriorates. The insurer funds the safety net their denials necessitate.
The Department of Recovery is the courthouse.
A federally-staffed Recovery Coordination Office to absorb IRE overflow, aggregate pattern data that converts individual fraud into prosecutable systemic fraud, and administer the mandatory board reporting pipeline the Amendment requires.
H.R. 6852 is the clinical floor.
It establishes that FDA-approved wound care treatments are covered Medicare benefits. Without it, the enforcement mechanisms above have no clinical standard to enforce. Without S.3829 and the Amendment, H.R. 6852 is a payment rule insurers can still delay and deny around.
S.3829 — Corporate Crimes Against Healthcare Act
Sponsors: Sen. Elizabeth Warren (for herself, Sen. Blumenthal, Sen. Markey, Sen. Merkley, and Sen. Welch)
The Corporate Crimes Against Healthcare Act targets the executives and corporate structures that profit from patient harm. It creates the enforcement mechanism that makes wrongful denial a crime with real consequences — not just a line item in a settlement.
- Unjust Enrichment Clawback: If a healthcare company experiences a "triggering event" — patient harm, bankruptcy, or fraud — the Attorney General or any State AG may claw back all covered compensation received by executives during the preceding or succeeding 10 years.
- Criminal Penalty: Any covered party whose actions contributed to a triggering event that results in the death or injury of a patient faces 1–6 years imprisonment.
- Civil Penalty: Up to 5 times the amount of any clawback authorized — creating the 500% penalty that capitalizes the Patient Safety Buffer Fund.
- Mandatory Ownership Transparency: Requires specified healthcare entities to annually report mergers, acquisitions, ownership changes, and financial structures — with a $5,000,000 penalty for false or missing reports.
- Moral Injury Study: Requires the HHS Inspector General to evaluate profit-driven practices in healthcare delivery and report to Congress — including prior authorization abuse, upcoding, AI-driven denials, and insurers' efforts to evade state corporate practice of medicine laws.
The gap S.3829 leaves open: S.3829 punishes the corporation and its executive leadership. It does not reach the individual physician who signs the denial letter — the medical director who excludes qualifying clinical data on procedural pretexts and faces no personal accountability for the harm that follows. That gap is precisely what the Clinical Integrity Amendment closes.
The Break Up Big Medicine Act
Sponsors: Sen. Elizabeth Warren and Sen. Josh Hawley — one of the most politically unlikely alliances in recent legislative history, united by what the bill's findings call "an unprecedented wave of consolidation."
The fact that Warren and Hawley are co-sponsors of the same healthcare bill tells you something important: the structural corruption of vertical integration in healthcare is not a partisan issue. It is a market capture issue. The left sees patient exploitation. The right sees monopoly. Both are correct. The bill exists because both diagnoses point to the same cure.
What It Does
The Break Up Big Medicine Act makes it unlawful for any person to simultaneously own or control both a healthcare provider (or management services organization) and an insurance company, pharmacy benefit manager, or prescription drug wholesaler. Companies in violation have one year to divest.
- Structural Separation: Prohibits common ownership of insurers or PBMs with medical providers. Prohibits common ownership of drug wholesalers with medical providers. The vertical integration that created UHG's empire — insurer + PBM + physician employer + data infrastructure — becomes illegal.
- Hard Divestment Deadline: One year from enactment. Non-compliance triggers an automatic 10% monthly profit escrow, held until divestment occurs. If divestment still doesn't happen, a court-appointed trustee executes the sale.
- Private Right of Action: Individual patients harmed by violations can sue directly — and may recover treble damages plus attorney's fees. This is not a waiting-for-the-government mechanism. Patients can be the enforcement arm.
- FTC + DOJ Joint Enforcement: Both agencies have concurrent jurisdiction to bring civil actions. State attorneys general can also sue as parens patriae on behalf of state residents.
- Disgorgement: Courts may order companies to disgorge all revenue received from entities subject to divestment during the period of violation — not just fines, but stripping the profit from the illegal structure retroactively.
- Quarterly Congressional Reporting: The FTC and DOJ must submit quarterly compliance reports to Congress — creating an ongoing public accountability mechanism.
- Future Blocking Authority: FTC and DOJ gain explicit authority to block any future action that would recreate the prohibited conflicts of interest — closing the re-acquisition loophole.
Congressional Findings (from the Bill Text)
- As of 2023, one conglomerate controls approximately 10% of all American physicians — the single largest employer of physicians in the nation.
- More than three-quarters of all American doctors are now employed by corporate entities.
- The 3 largest PBMs process nearly 80% of all prescription drug claims.
- The 3 largest drug wholesalers control 98% of the U.S. drug distribution market.
- The FTC has found that vertically integrated PBMs have both the ability and incentive to steer business to their own affiliated pharmacies, reducing competition and increasing drug costs.
- Private insurers use employed physicians to intensively document enrollees' medical conditions — generating inflated payments from the Federal government without improving care quality. (The upcoding mechanism, confirmed in the bill's own findings.)
H.R. 6852 — Advanced Wound Care and Regenerative Medicine Access and Reform Act
Sponsor: Rep. Evans of Colorado
Why This Bill Is Personal
Apligraf — an FDA-approved skin substitute product (PMA P950032S016, cleared 2000) — was denied by UnitedHealthcare for 17 months while non-healing wounds progressed to bone demineralization described as "cuttable with a scalpel." When Apligraf was finally approved, it closed those wounds in two weeks. H.R. 6852 directly addresses the payment and coverage framework for products like Apligraf under Medicare. The Denial on Trial framework names this bill explicitly: H.R. 6852 addresses the clinical harm. The Clinical Integrity Amendment and S.3829 provide the enforcement mechanism that gives it teeth.
📋 What the FDA Said — Starting in 1995
The following facts are drawn directly from the FDA's Summary of Safety and Effectiveness Data for Apligraf® (PMA P950032, Supplement S016). This is not advocacy. This is the federal regulatory record.
Aug 7, 1995
FDA authorized expedited review based on Apligraf's potential to provide "a clinically important advance over existing alternatives" for neuropathic diabetic foot ulcers. The urgency was recognized 25 years before UHC's denial.
May 22, 1998
FDA approved Apligraf for venous leg ulcers — skin ulcers due to venous insufficiency of greater than 1 month duration that have not adequately responded to conventional therapy. Exactly the indicated use UHC denied.
June 20, 2000
FDA approved Apligraf for diabetic foot ulcers following a prospective, randomized, multi-center controlled clinical trial. Full federal approval issued. Standard of care established.
2018–2019
UnitedHealthcare denied Apligraf for 17 months — 18–21 years after federal approval — while wounds progressed to bone demineralization. When finally approved, the wounds closed in two weeks.
The Clinical Trial Data UHC Ignored
The FDA's pivotal trial (Protocol 95-DUS-001, n=208 patients) demonstrated results confirmed and refined by the manufacturer's ongoing real-world evidence program:
- 56.3% wound closure for Apligraf patients vs 37.5% for control at 12 weeks (p=0.0082)
- Median time to 50% wound closure: 65 days for Apligraf vs 90 days for control (p=0.0026)
- Amputation incidence at 6 months: 6.3% vs 15.6% for control (p=0.028) — Apligraf reduces amputation risk by roughly 60%
- Osteomyelitis incidence at 6 months: 2.7% vs 10.4% for control (p=0.04) — Apligraf reduces bone infection risk by roughly 75%
- No immune rejection observed in any patient. No antibody responses against bovine collagen or human cell components.
Note: The 2000 FDA approval data has since been further validated by the manufacturer's real-world evidence program using large-scale EMR databases. The efficacy profile has strengthened, not weakened, with 25 years of post-market use. The case against the denial gets stronger over time, not weaker.
UHC denied a treatment the FDA recognized as a "clinically important advance" in 1995, approved in 1998 and 2000, that reduces amputation risk by 60% and bone infection risk by 75% in clinical trials — citing it as "not medically necessary" for 17 months. The patient subsequently developed osteomyelitis severe enough that bone was described as "cuttable with a scalpel." The treatment was proven to prevent that exact outcome. When it was finally approved, wounds closed in two weeks.
What It Does
H.R. 6852 reforms how Medicare covers and pays for skin substitute products — cellular, tissue, biological, or synthetic materials applied to wounds and intended to remain in the wound bed. This includes advanced wound treatments like Apligraf that have been FDA-cleared and standard-of-care for decades but remain subject to arbitrary insurance denial and delayed access.
- Medicare Coverage Established: Formally adds skin substitute products as a covered Medicare benefit under Section 1861(s)(2) of the Social Security Act — closing the ambiguity that allows insurers to deny FDA-approved wound treatments as "experimental" or "not medically necessary."
- Standardized Payment: Creates a volume-weighted average payment methodology based on 2023 Medicare data, with annual CPI adjustments — replacing the current pricing chaos that enables over- and under-payment alike. Effective January 1, 2026.
- Site-of-Care Parity: Requires equivalent reimbursement for skin substitute products regardless of the care setting — preventing the practice of denying outpatient access to treatments that would be covered in a hospital setting.
- Program Integrity: Identifies the top 3% of skin substitute product billers as "outlier providers" and requires CMS to conduct prepayment review and, where warranted, prior authorization — targeting fraudulent billing on the provider side while protecting legitimate patient access.
- FDA Streamlining: Directs FDA to conduct a comprehensive review within 18 months of the approval processes for human cellular and tissue allografts — with specific attention to tiered risk frameworks, streamlined application requirements, and reduced duplicative clinical trial burdens. Guidance to be finalized within 36 months.
- Congressional Accountability: Requires a report to the Senate HELP Committee and House Energy & Commerce Committee on findings, recommendations, and estimated patient access impacts.
The Legislative Architecture Connection
H.R. 6852 establishes the clinical right — that FDA-approved wound care treatments are covered Medicare benefits with predictable payment. S.3829 and the Clinical Integrity Amendment establish the enforcement mechanism — that a physician who denies a covered, medically necessary treatment faces license consequences. Without H.R. 6852, the enforcement mechanism has no clinical standard to enforce. Without S.3829 and the Amendment, H.R. 6852 is a payment rule that insurers can still delay, deny, and appeal around.
The Clinical Integrity & Patient Safety Amendment
Proposed Addition to S.3829 — Drafted by Michael Kissling, AbilityForge.net
⚡ The Critical Bolt
The entire Wrongful Denial Echo Chamber operates because the physician who signs the denial letter faces no personal professional consequence. A corporate reviewer can exclude objective clinical data on procedural pretexts, issue a denial the IRE will overturn in seconds, and walk away with their license intact. The Clinical Integrity Amendment closes this gap by making every IRE overturn a self-executing referral to the State Medical Board. This is not additional bureaucracy — it is the equivalent of bar discipline for an attorney who hides exculpatory evidence. The mechanism only works when the person pulling the trigger can lose their license for doing so.
§ 1 — Prohibition of Prior Knowledge Omission
When a Medicare Advantage organization or ERISA plan has previously approved a specific functional classification, medical baseline, or K-Level, that classification becomes an Established Medical Fact for a minimum of 12 months.
In plain English: If UHC acknowledges a patient's K3 functional mobility status in March, it may not deny a permanent prosthetic in September by claiming the same mobility threshold is unmet — unless it produces new clinical evidence of decline. A denial issued against a prior-established medical fact without documentation of regression is void ab initio and triggers Buffer Fund penalties.
This provision directly addresses the documented Kissling v. UnitedHealthcare case: UHC approved K3 status in March 2023, then denied the permanent prosthetic in September 2023 while possessing that prior knowledge — a textbook Prior Knowledge Omission.
§ 2 — The Clinical Integrity Rule (The "Act 146 Standard")
Any adverse benefit determination based on medical necessity must be reviewed by a physician holding current, valid Board Certification in the same or directly relevant specialty as the treating physician. The reviewing physician must certify under penalty of perjury that they have reviewed all objective clinical data submitted — including PT/OT evaluations, imaging, and standardized assessment scores.
- A pediatrician may not review an adult bariatric claim.
- A general practitioner may not review a specialized prosthetic claim.
- A non-vascular physician may not review a vascular surgical necessity determination.
- An ocular plastic surgeon may not review a lymphedema surgery for a breast cancer patient.
That last example is not hypothetical. See Dr. Elizabeth Potter's documented peer-to-peer call in the Independent Voices section below.
§ 3 — The Patient Safety Buffer Fund
Upon submission of a medical necessity override by the treating physician, coverage is provisionally granted through the Patient Safety Buffer Fund while the determination is under review. Patients shall not be denied care during the appeals process.
If the denial is upheld:
The treating provider repays the Buffer Fund in full.
If the denial is overturned:
The insurer reimburses the Buffer Fund at 300% of the claim rate. The insurer funds the safety net their denials require.
§ 4 — The Administrative Cure Mandate
A plan may not issue a final denial for administrative reasons without first providing a 48-hour Cure Period to correct any clerical or procedural deficiency. If a plan classifies a denial as "administrative" to circumvent the Clinical Integrity review — when the record contained sufficient clinical data to warrant medical review — the plan faces a civil monetary penalty of $10,000 per violation.
This closes the loophole by which insurers reject claims on paperwork pretexts to avoid the specialty-matching and data-review requirements of § 2. In the 2023 KFF data, "Administrative reason" accounted for 18% of all ACA Marketplace denials — second only to the vague "Other" category.
§ 5 — Physician Accountability: The Malpractice Trigger
This is the critical section. The bolt that disassembles the chamber.
Any physician acting as a medical director or reviewer who issues a denial that is subsequently overturned by an IRE — due to a demonstrable failure to adhere to established clinical standards or failure to review submitted evidence — shall be deemed to have engaged in Unprofessional Conduct.
- Mandatory Board Reporting: The IRE shall be statutorily required, upon issuing an overturn, to report the name and license number of the reviewing physician to their respective State Medical Board for investigation into malpractice and negligence.
- Pierce the Corporate Veil: Reviewing physicians shall not be shielded from personal liability for patient harm caused by denials issued in contradiction to established medical consensus — regardless of their employment relationship with the plan.
"A prosecutor who hides exculpatory evidence faces disbarment. A corporate reviewer who ignores qualifying clinical data faces nothing — until now."
— Clinical Integrity & Patient Safety Amendment
The industry average IRE overturn rate is 81.7%. UnitedHealthcare's rate is 85.2%. Those are not medical disagreement rates. They are fraud rates — executed by physicians whose licenses have never been at risk. This single provision changes that calculus permanently.
Denial on Trial — A Framework for Medical Due Process
Proposed by Michael Kissling, AbilityForge.net | In support of S.3829 and the Clinical Integrity & Patient Safety Amendment
The Core Problem: A Rigged Proceeding
The current insurance appeals system asks patients to prove they deserve care — while the insurer who denied them controls the evidence, employs the reviewing physician, and faces no consequence if they are wrong. This is not a medical judgment system. It is a financial extraction system dressed in clinical language.
The Denial on Trial framework applies the logic of Gideon v. Wainwright to healthcare: you cannot have a fair proceeding when one side has no counsel. The current IRE system asks a single body to be both judge and patient advocate simultaneously — structurally identical to the injustice that created the public defender system.
Current System vs. Denial on Trial Model
| Role | Current System | Denial on Trial Model |
|---|---|---|
| IRE Role | Neutral arbitrator | Patient advocate (Public Defender) |
| Burden of Proof | Patient must prove need | Insurer must prove denial is justified |
| Medical Evidence | Reviewer may exclude data outside their note | All submitted clinical data reviewed under penalty of perjury |
| Ruling Authority | IRE acts as judge and advocate simultaneously | Administrative Law Judge rules independently |
| Physician Accountability | No consequence for wrongful denial | Mandatory State Medical Board referral on IRE overturn |
| Fraud Mechanism | Prior Knowledge Omission goes unpunished | Suppression of known qualifying evidence = malpractice trigger |
The Three Roles
- Prosecution (The Insurer): Files the denial — and bears the burden of proving it is justified against the established medical record.
- Public Defender (The IRE): Advocates for the patient's complete clinical record against that denial — as a Public Defender, not a neutral arbitrator.
- Adjudicator (Administrative Law Judge): Rules independently — with authority to trigger financial penalties and mandatory board reporting.
The Capacity Problem: Why We Need a Department of Recovery
S.3829's higher stakes — 300–500% clawbacks, mandatory board reporting, malpractice triggers — will cause insurers to fight every case harder. The current IRE infrastructure, already under strain, will be overwhelmed.
Private IREs rule case by case. They do not aggregate patterns. They do not notice that a single reviewing pediatrician is adjudicating hundreds of adult bariatric claims monthly. A federally-staffed Recovery Coordination Office would:
- Absorb IRE overflow volume created by the new penalty structure
- Maintain cross-case pattern data that converts individual fraud into prosecutable systemic fraud
- Administer the Patient Safety Buffer Fund with federal accountability
- Feed the mandatory board reporting pipeline the Clinical Integrity Amendment requires
"Long after the sensationalism of a verdict fades, the legislative reform that finally dismantles the Wrongful Denial Echo Chamber is what will endure."
— Michael Kissling, AbilityForge.net
The PSI Briefing — Documented Evidence of Prior Knowledge Omission
Submitted to the Senate Permanent Subcommittee on Investigations | March 2026 | Michael Joseph Kissling, Medicare Advantage Beneficiary & Healthcare Advocate
85.2%
UHC prior auth overturns
(KFF 2023)
81.7%
Industry average
overturn rate
~29%
Traditional Medicare
overturn rate
$1.1M+
Taxpayer cost
— this case alone
This is not a dispute over medical judgment. It is a documented mechanism of deceptive business practice — executed with paper trail proof of intent.
The Fraud Mechanism: Prior Knowledge Omission
UHC medical directors deny legitimate claims by deliberately ignoring qualifying medical information already in their possession. This is not administrative error. It is documented, repeatable policy.
- The insurer acknowledges a patient's qualifying status through an approval decision
- The insurer then denies a directly related claim while possessing that prior knowledge
- The reviewing physician excludes objective clinical data on procedural pretexts
- The patient is forced through an appeals process that functions as a delay weapon
- The insurer offloads the financial cost of resulting harm onto taxpayers
The Documented Case: Kissling v. UnitedHealthcare — The Paper Trail
UHC approves learner prosthetic — officially acknowledging K3 functional mobility status (AMPnoPRO score: 35). This classification is mandatory knowledge in UHC's possession.
Six days after K3 establishment: UHC changes beneficiary's plan, making all existing physicians and physical therapists out-of-network. Care continuity disrupted.
UHC denies transition to permanent tertiary prosthetic — claiming beneficiary does not demonstrate sufficient functional ability. Denial issued while UHC possesses K3 approval AND updated K4 PT evaluation (AMPnoPRO: 44/47).
Updated PT evaluation confirms advancement to K4 status (AMPnoPRO: 44/47). UHC reviewer explicitly refuses to acknowledge this data because it was not written in his specific office note.
UHC final denial letter states: "Medicare Guidance says that the requested computerized knee advanced feet exceed your needs" — a statement made with documented prior knowledge that patient was K3-K4, in direct violation of Medicare Policy Article A52496.
Maximus Federal Services (IRE) immediately overturns UHC denial. Finding: medically necessary. This overturn is equivalent to summary judgment — UHC's position was indefensible.
Medicare lowers microprocessor knee standard from K3 to K2 — meaning the patient would have qualified under even the future relaxed standard. UHC's denial had no medical or regulatory basis at any point in time.
The Smoking Gun: Dr. Stockhausen's Documentation
The attending physician, Dr. Sean T. Stockhausen, documented in writing that the UHC peer-to-peer reviewer confirmed he remembered the K4 argument — and then stated he could not use objective PT data, including walking speed and AMPnoPRO score, unless it was written directly in his own office note. He subsequently amended his office note specifically to include the AMPnoPRO score.
This is the echo chamber mechanism documented by the treating physician himself: standardized, Medicare-approved assessment scores excluded on a procedural pretext manufactured by the corporate reviewer. Under the Clinical Integrity Amendment § 2, this action would be void and trigger mandatory board reporting.
The Cascading Taxpayer Cost
The Wrongful Denial Echo Chamber does not save money. It shifts costs from the insurer onto the public:
- A denied $55,000 iliac vein stenting surgery (85–90% five-year patency rate) triggered cascading wound care failures
- A 17-month delay in FDA-standard Apligraf wound treatment (PMA P950032S016, established 2000) allowed infection to progress until bone pathology showed demineralization described as "cuttable with a scalpel"
- When Apligraf was finally approved, it closed the wounds in two weeks — vindicating the standard UHC suppressed for 17 months
- The denied permanent prosthetic resulted in statistically preventable falls and the loss of physical capacity to protect an autistic child from danger
- Total taxpayer-funded cost: $1.1 million and climbing — on a case that began with a $55,000 denial
Independent Voices
The doctors, creators, and advocates using their platforms to make the invisible visible — credentialed, fearless, and reaching millions.
Dr. Glaucomflecken
Physician & Satirist (Dr. Will Flanary, Ophthalmologist) — YouTube, TikTok, X
Dr. Flanary uses sharply-written satirical sketches to dramatize how the insurance industry operates from the inside. His "30 Days of US Healthcare" series breaks down each mechanism of denial in accessible, often devastating comedy.
Day 26: United Healthcare Denies Everything
A satirical portrait of a private health insurance employee denying life-sustaining care for absurd and bureaucratic reasons — including requiring a patient to prove they "still have Type 1 diabetes," refusing to approve a pacemaker battery ("maybe the heart's figured it out by now"), and making patients wait 6–8 weeks to appeal a denial for insulin.
Watch on YouTube →Day 12: Automated Claim Denials
A sketch depicting an automated denial system where medical directors deny claims without reviewing clinical documentation — 300,000 denials in two months, at 1.2 seconds per denial. The company's goal: "blanket deny everything," because only 5% of patients ever appeal.
Watch on YouTube →Day 5: Prior Authorizations
The invention of prior authorization portrayed as a deliberate strategy to wedge into industries "we know nothing about." Characters openly acknowledge they are "practicing medicine without a license" and that their tool is not for rare treatments — it's designed to "generate wealth by needlessly delaying routine medical care."
Watch on YouTube →Dr. Elizabeth Potter
Plastic & Reconstructive Surgeon — Breast Cancer & Lymphedema Specialist
Dr. Potter isn't a satirist — she recorded a real peer-to-peer call with a UHC reviewing doctor and exposed him as an ocular plastic surgeon (eyelid surgeon) reviewing a lymphedema surgery for a breast cancer patient. When UHC demanded she take the video down and publicly apologize, she refused. This is direct documentation — precisely the kind of mismatched specialty review that the Clinical Integrity Amendment § 2 would make a reportable offense.
Dr. Exposes UnitedHealthcare in ONE Call
- The UHC reviewing doctor refused to provide his name, claiming it was "for his own protection."
- Dr. Potter's patient had a 40% risk of developing lymphedema post-cancer treatment. The preventative surgery — lymphovenous bypass — would reduce that risk to 10%.
- The reviewing doctor was an ocular plastic surgeon, unfamiliar with lymphedema, who had never performed the procedure and did not treat breast cancer patients.
- UHC sent Dr. Potter a cease-and-desist demanding the video be taken down and a public apology issued. She refused.
Dr. Caleb Masterson, DO
Board-Certified Otolaryngologist / Head & Neck Surgeon · ENT Center of Northwest Alabama, Florence, AL · @dr.masterson — 105K Instagram followers
Dr. Masterson is a board-certified ENT and Head & Neck surgeon in private practice in Florence, Alabama — an Adjunct Clinical Professor of Anatomy at Kansas City University College of Medicine, with peer-reviewed research published in national journals. With 105K Instagram followers and an active presence on Facebook and TikTok, he uses short-form video to make a forensic legal argument that most lawyers haven't made publicly: that wrongful denial by insurers meets every legal element of insurance fraud — not metaphorically, but by the actual statutory definition. His content is precise, sourced, and aimed directly at the mechanism.
"Can we all agree that fraud is bad?"
42.8K views · 1.2K likes · 167 shares · #healthcare #privatepractice #doctor #surgeon
Dr. Masterson walks through the statutory legal elements of fraud — then applies each one directly to insurer wrongful denial behavior. The argument is not rhetorical. He maps the legal standard element by element:
| Legal Element | Traditional Insurance Fraud | Insurer Wrongful Denial |
|---|---|---|
| Scienter (knowledge of falsity) |
Knowingly falsifies — "this procedure was needed" or "my house burned down" | Knowingly denies — "not medically necessary" when 90% of denials are overturned on appeal, proving knowledge of invalidity |
| Material Misrepresentation | "A loss occurred" (when it didn't) | "This is not medically necessary" (when it is) |
| Intent to Defraud | Purpose to obtain money not owed — burning down a house to collect | Purpose to retain premiums owed — CEOs bonused on maintaining profitability; appeal rate only 0.2% so patients don't push back |
| Reliance | Insurer legitimately has to pay the claim | Patient relies on the false denial and foregoes care — only 0.2% of denials are ever challenged |
| Damages & Causation | Insurer suffers financial loss caused by the false claim | Patient suffers financial loss or death. AMA study: a third of denials lead to significant loss of life, limb, or bodily function. The false denial is the direct cause. |
His closing question — directed at attorneys:
"I understand there are a lot of rules — like they're not making medical decisions, they can't be sued, no malpractice. But when the burden or the precedent of fraud is the same between someone trying to get money from the insurance company and the insurance company keeping money back — why doesn't this activity qualify? Attorneys that follow me, give me some reasons as to why this burden of activity does not qualify."
— Dr. Caleb Masterson, DO
This is the gap the Clinical Integrity Amendment § 5 closes — not by creating new law, but by connecting the existing legal standard to an individual physician who signs a denial. The insurer hides behind the shield that it isn't making medical decisions. The Amendment pierces that shield: if a licensed physician certifies under penalty of perjury that they reviewed the clinical record and the IRE immediately overturns them, the certification was false. The fraud elements Dr. Masterson describes above now attach to a named, licensed individual — not a corporation.
By the Numbers: United Healthcare Denial Data
- UHC denies 32% of all claims — nearly double the industry average of ~18%.
- For elective surgeons, UHC's denial rate can reach 80%.
- Nearly half of all denied claims stem from the prior authorization process.
- AI-driven claim denials — autonomous systems rejecting claims "without proper contextual understanding" — are now a listed systemic strategy.
Read the Nemedic Analysis by Brad Bichey → Read the ValuePenguin Data →